STOCK TITAN
  1. Home
  2. News
  3. AVIR

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022
conferences earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development
management clinical trial
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications
IMPACT
SENTIMENT
AVIR : Nasdaq
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
Stock AVIR logo
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

#4189 Ranked by Market Cap
#4631 Ranked by Stock Gains
N/A Ranked by Dividends

AVIR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.